Lead Product(s) : Hydroxyurea
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Acquisition
Norgine Strengthens Rare Disease Portfolio with Acquisition of Theravia
Details : Through the acquisition, Norgine will have six core products in its rare disease portfolio, which includes Siklos (hydroxyurea) is being indicated for the treatment of sickle cell anemia.
Product Name : Siklos
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
April 15, 2025
Lead Product(s) : Hydroxyurea
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Enasidenib,Hydroxyurea
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 IDHENTIFY study evaluating IDHIFA®(enasidenib) plus best supportive care vs conventional care regimens, which include azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint.
Product Name : Idhifa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Enasidenib,Hydroxyurea
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
